Sponsorship Focuses on Website Link to Introduce Consumers to Progesterone Compounding Kits
MCLEAN, Va., April 14 /PRNewswire/ -- As the leading voice for women and men facing infertility, RESOLVE: The National Infertility Association (RESOLVE) announces their partnership with Woburn, MA-based CutisPharma, Inc. This relationship will introduce CutisPharma, Inc., makers of progesterone suppository compounding kits for in-pharmacy use, to RESOLVE constituents.
"RESOLVE applauds CutisPharma for their innovativeness in developing a product that may benefit millions of Americans needing progesterone products," said Barbara Collura, RESOLVE's Executive Director. "I look forward to working closely with CutisPharma to assist women and men in their family building journey."
CutisPharma estimates that over 1.5 million progesterone suppository prescriptions for compounding are written in the U.S. annually. CutisPharma's progesterone suppository compounding kits are available in 25mg, 50mg, 100mg, 200mg, and 400mg strengths allowing maximum flexibility for physicians.
"We are pleased to partner with RESOLVE in increasing our product awareness among RESOLVE members, supporters, and healthcare professionals," said Dr. Indu Muni, CEO of CutisPharma. "As the leader in providing family building support and information to the public, RESOLVE is a trusted source. We are pleased to be included as a resource for RESOLVE."
About RESOLVE: The National Infertility Association
Founded in 1974, RESOLVE: The National Infertility Association, headquartered in McLean, VA, is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with infertility in the United States. Each year, RESOLVE and its nationwide network of affiliates and chapters handle more than 1.5 million contacts from people seeking information and help. For more information, visit the RESOLVE website at www.resolve.org.
About CutisPharma, Inc.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST(R) - Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending. For more information on CutisPharma please visit our website at www.firstprogesterone.com or www.cutispharma.com.
|SOURCE CutisPharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved